Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.

AIDS (London, England) - 6 Jul 2001

Conway B, Wainberg M A, Hall D, Harris M, Reiss P, Cooper D, Vella S, Curry R, Robinson P, Lange J M, Montaner J S

Abstract excerpt

OBJECTIVE: To evaluate the development of phenotypic and genotypic resistance to zidovudine, didanosine and nevirapine as a function of the virologic response to therapy in a group of drug-naive individuals receiving various combinations of these agents. DESIGN: All patients were enrolled in a double-blind controlled randomized trial (the INCAS study) and were selected for detailed resistance studies based on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Didanosine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Drug Resistance, Microbial

Share to Drug Therapy, Combination

Share to Nevirapine

Share to Reverse Transcriptase Inhibitors

Share to Zidovudine

Source

Identifiers

PMID: 11426071
DOI: 10.1097/00002030-200107060-00008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.PMID 11426071Read ↗

Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.Semantic proximity Read ↗

HIV-1 drug resistance in newly infected individuals.Semantic proximity Read ↗

Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.Semantic proximity Read ↗

Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.Semantic proximity Read ↗

Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies.Semantic proximity Read ↗

Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.Semantic proximity Read ↗

Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study.Semantic proximity Read ↗

Antiviral drug resistance.Semantic proximity Read ↗

Development of resistance mutations to nevirapine as part of triple-drug therapy in children.Semantic proximity Read ↗

Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.Semantic proximity Read ↗

Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.Semantic proximity Read ↗

Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.